Barycela vaccine does not contain antibiotics - the optimal safety solution for children

TS. Đỗ Tuấn Đạt - Chuyên gia vaccine và sinh phẩm y tế và TS. Phạm Thị Phương Thảo |

Vaccination safety is always a concern for parents, especially for children with sensitive motives or a history of allergies. And, the Barycela chickpea vaccine is the optimal solution.

Many parents are worried when they know that some vaccines containing antibiotics can cause reactions from crying, breastfeeding, poor sleep to rashes after vaccination.

In particular, in infants, these signs are easily confused with normal physiological reactions, but if not detected promptly, allergies can become severe, even leading to anaphylactic shock, although very rare.

Some popular vaccines such as measles, positive Agency, rubella, chickenpox, Japanese encephalitis or inactively paralyzed patients still contain certain antibiotic resistance such as Neomycin, Gentamicin, Streptomycin, Kanamycin, Erythromycin and others in the vaccine ingredients.

Meanwhile, most parents do not know which antibiotic their children are sensitive to or allergic to, unless they have had allergic reactions at previous uses.

Why are antibiotics in the vaccine's ingredients?

Antibiotics in vaccines are not used to treat diseases but are used to prevent bacteria or fungi from entering the process of growing viruses or cells. After the production process, most antibiotics are removed and only have a minimum remaining level, meeting strict quality control standards.

However, no antibiotic residue level has been recognized as absolutely safe for children. Therefore, vaccine guidelines still recommend contraindications for children allergic to any ingredient in the vaccine, including antibiotics.

This ensures safe vaccination but limits access to vaccine for some sensitive children.

trend of antibiotic-free vaccines

Modern vaccine production technology is aiming to completely eliminate antibiotics thanks to process improvements. The production process ensures strict sterilization, a closed system, single-use material technology and strict microbiological monitoring methods have helped create new high-quality products, minimizing the risk of allergies.

The new generation chickenpox vaccine - Barycela produced by GC Biopharma (Korea) currently distributed by NAV VAT GROUP Company in the Vietnamese market is a clear demonstration of the trend of antibiotic-free vaccines.

The advancement of modern medicine not only brings effective disease prevention solutions but also creates trust and peace of mind for families. Understanding correctly, choosing the right vaccine so that each vaccination dose will become a solid shield to protect public health.

Barycela chickpea vaccine - a safe choice for children

Barycela, the chickpea vaccine that does not contain antibiotics, has many obvious benefits:

· Not contraindicated for children who are sensitive to antibiotics.

· Reduces the risk of allergic reactions related to antibiotics.

· Especially suitable for children - the group of subjects that need the highest level of safety.

Completely eliminating antibiotics in the vaccine helps parents feel secure - each shot is both effective in disease prevention and maximum safety.

TS. Đỗ Tuấn Đạt - Chuyên gia vaccine và sinh phẩm y tế và TS. Phạm Thị Phương Thảo
TIN LIÊN QUAN

Important improvements with the Barycela vaccine - The key to WHO-PQ

|

Improve production processes to improve the quality of WHO-PQ-certified vaccines - a lesson from the Barycela chickenpox vaccine of GC Biopharma (Korea).

Barycela chickenpox vaccine - a suitable and reliable choice

|

The new generation of the Barycela chickenpox vaccine is produced by GC Biopharma (Korea), using the MAV/06 vaccine.

New updated points in the WHO Guidelines for chickenpox vaccines

|

On November 21, 2025, the World Health Organization (WHO) issued an updated WHO Position Paper for the chickenpox vaccine to replace the 2014 version.

Important improvements with the Barycela vaccine - The key to WHO-PQ

TS.BS. Dương Hữu Thái – Viện trưởng Viện Vắc xin và Sinh phẩm Y tế và TS. Phạm Thị Phương Thảo |

Improve production processes to improve the quality of WHO-PQ-certified vaccines - a lesson from the Barycela chickenpox vaccine of GC Biopharma (Korea).

Barycela chickenpox vaccine - a suitable and reliable choice

TUỆ MẪN |

The new generation of the Barycela chickenpox vaccine is produced by GC Biopharma (Korea), using the MAV/06 vaccine.

New updated points in the WHO Guidelines for chickenpox vaccines

TS Đỗ Tuấn Đạt - Chuyên gia vaccine và sinh phẩm y tế |

On November 21, 2025, the World Health Organization (WHO) issued an updated WHO Position Paper for the chickenpox vaccine to replace the 2014 version.